Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Eupraxia Pharmaceuticals ( (TSE:EPRX) ) has issued an update.
On February 20, 2026, Eupraxia Pharmaceuticals closed a public offering of 7,607,145 common shares, including full exercise of the underwriters’ option, and 1,428,571 pre-funded warrants, raising gross proceeds of about US$63.2 million before fees. The securities were priced at US$7.00 per common share and US$6.99999 per pre-funded warrant, with Cantor Fitzgerald & Co. and LifeSci Capital acting as joint bookrunners alongside two co-managers.
The company plans to use the net proceeds primarily to advance EP-104GI for Eosinophilic Esophagitis through ongoing preclinical work, Phase 2 studies, Phase 3 preparations, and manufacturing and market development ahead of a potential launch. Funds will also support expanded clinical studies of EP-104GI in additional GI indications, further pipeline R&D, business development, intellectual property expansion, and general corporate purposes, bolstering Eupraxia’s resources for future growth as disclosed in the February 23, 2026 report.
The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.
Spark’s Take on TSE:EPRX Stock
According to Spark, TipRanks’ AI Analyst, TSE:EPRX is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, ongoing losses and cash burn), partially offset by a conservatively levered balance sheet. Technicals are the main positive, showing a clear uptrend and constructive momentum, while valuation is constrained by negative earnings and no dividend data.
To see Spark’s full report on TSE:EPRX stock, click here.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a Canadian biopharmaceutical company based in Victoria, British Columbia, focused on developing therapeutics for gastrointestinal and related inflammatory conditions. Its lead candidate, EP-104GI, targets Eosinophilic Esophagitis and other gastrointestinal indications, positioning the company in the specialty GI and immunology treatment market.
Average Trading Volume: 93,258
Technical Sentiment Signal: Buy
Current Market Cap: C$553.1M
See more data about EPRX stock on TipRanks’ Stock Analysis page.